Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Neuroendocrine Prostate Cancer × Gallium × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Endocrine 1

Conditions

Metastatic Neuroendocrine Prostate Cancer 1

Interventions

gallium Ga 68 dotatate 1 gallium 68 PSMA-11 1 copper dotatate CU-64 1 Metoclopramide 1 Lutetium-177 1 Lutetium 1 Gonadotropin-Releasing Hormone 1 Gallium 1 Antiemetics 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Novartis

Phase 1 Active not recruiting

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡